<DOC>
	<DOC>NCT01780948</DOC>
	<brief_summary>Hypothesis : In renal transplantation recipient who received immunosuppressive drug "certican" and have hypercholesterolemia will get lipid lower drug-HMG Co-A reductase inhibitors. Because atorvastatin and everolimus have metabolism via Cytochrome P450 subfamily 3A4 both, so investigator made the hypothesis that when patients received everolimus with atorvastatin will change area under the time concentration curve of everolimus.</brief_summary>
	<brief_title>Pharmacokinetic of Everolimus and Atorvastatin Co-administration</brief_title>
	<detailed_description>Population : Thai postrenal transplantation recipient who received everolimus and have hypercholesterolemia in posttransplantation clinic at Faculty of Medicine, Chulalongkorn University. Study Design : Experimental study, Two-sample crossover study Sample size calculation :N = 18 Primary outcome : 12-hour area under the time concentration curve of everolimus Secondary outcome : renal function (serum creatinine, creatinine clearance) Method : 1. Patients will random to everolimus or everolimus with atorvastatin 20 mg arm for 1 month. 2. Take blood sample for everolimus concentration at time 0,0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 hour 3. After first blood sample, patients will received everolimus only for 1 month (wash out period) 4. Patients will switch to another arm eg.patient who had received everolimus will switch to everolimus with atorvastatin 20 mg for 1 month 5. Take blood sample for everolimus concentration at time 0,0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 hour 6. Everolimus level will analyse for 12-hour AUC of everolimus.</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Post renal transplantation recipient who received immunosuppressive drug Everolimus and has hypercholesterolemia Co everolimus level within 312 ng/mL Informed consent Patient can follow research methodology Patient don't want to participate in the study Post renal transplantation recipient who have normal lipid profile</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Drug Interaction</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Atorvastatin</keyword>
</DOC>